Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Mayo Clinic
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
NRG Oncology
Gustave Roussy, Cancer Campus, Grand Paris
Dartmouth-Hitchcock Medical Center
Stanford University
Centre Oscar Lambret
Mayo Clinic
National Institutes of Health Clinical Center (CC)
University of Michigan Rogel Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Vanderbilt-Ingram Cancer Center
University of Arizona
Thomas Jefferson University
Sun Yat-sen University
UNICANCER
City of Hope Medical Center
Cardarelli Hospital
Centre of Postgraduate Medical Education
Poitiers University Hospital
Fox Chase Cancer Center
Technische Universität Dresden
Universidad Rey Juan Carlos
Dana-Farber Cancer Institute
Ohio State University Comprehensive Cancer Center
University of Chicago
Case Comprehensive Cancer Center
Abramson Cancer Center at Penn Medicine
Ohio State University Comprehensive Cancer Center
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
University of California, San Diego
Ohio State University Comprehensive Cancer Center
European Organisation for Research and Treatment of Cancer - EORTC
University Health Network, Toronto
Groupe Oncologie Radiotherapie Tete et Cou
Washington University School of Medicine
Duke University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
NYU Langone Health